nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfentanil—CYP3A4—breast cancer	0.119	0.37	CbGaD
Alfentanil—ALB—breast cancer	0.104	0.323	CbGaD
Alfentanil—ABCB1—breast cancer	0.099	0.308	CbGaD
Alfentanil—CYP3A5—Lapatinib—breast cancer	0.0275	0.0564	CbGbCtD
Alfentanil—ABCB1—Toremifene—breast cancer	0.0246	0.0504	CbGbCtD
Alfentanil—CYP3A4—Exemestane—breast cancer	0.0212	0.0435	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0184	0.0377	CbGbCtD
Alfentanil—CYP3A7—Tamoxifen—breast cancer	0.0184	0.0377	CbGbCtD
Alfentanil—CYP3A4—Letrozole—breast cancer	0.018	0.037	CbGbCtD
Alfentanil—ABCB1—Lapatinib—breast cancer	0.0179	0.0367	CbGbCtD
Alfentanil—CYP3A4—Anastrozole—breast cancer	0.0161	0.033	CbGbCtD
Alfentanil—CYP3A4—Toremifene—breast cancer	0.0147	0.0302	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.0143	0.0293	CbGbCtD
Alfentanil—CYP3A7—Paclitaxel—breast cancer	0.0143	0.0293	CbGbCtD
Alfentanil—CYP3A7—Irinotecan—breast cancer	0.0141	0.0289	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.0141	0.0289	CbGbCtD
Alfentanil—CYP3A5—Tamoxifen—breast cancer	0.0138	0.0283	CbGbCtD
Alfentanil—CYP3A4—Fulvestrant—breast cancer	0.0137	0.028	CbGbCtD
Alfentanil—ALB—Irinotecan—breast cancer	0.0132	0.027	CbGbCtD
Alfentanil—ALB—Fluorouracil—breast cancer	0.0126	0.0259	CbGbCtD
Alfentanil—CYP3A4—Thiotepa—breast cancer	0.0122	0.025	CbGbCtD
Alfentanil—CYP3A4—Ixabepilone—breast cancer	0.0111	0.0229	CbGbCtD
Alfentanil—CYP3A4—Lapatinib—breast cancer	0.0107	0.022	CbGbCtD
Alfentanil—CYP3A5—Paclitaxel—breast cancer	0.0107	0.022	CbGbCtD
Alfentanil—CYP3A5—Irinotecan—breast cancer	0.0106	0.0217	CbGbCtD
Alfentanil—CYP3A7—Docetaxel—breast cancer	0.0103	0.0212	CbGbCtD
Alfentanil—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.0103	0.0212	CbGbCtD
Alfentanil—ABCB1—Vinorelbine—breast cancer	0.00993	0.0204	CbGbCtD
Alfentanil—ABCB1—Tamoxifen—breast cancer	0.00897	0.0184	CbGbCtD
Alfentanil—ABCB1—Mitoxantrone—breast cancer	0.00875	0.0179	CbGbCtD
Alfentanil—CYP3A4—Raloxifene—breast cancer	0.00813	0.0167	CbGbCtD
Alfentanil—CYP3A5—Docetaxel—breast cancer	0.00775	0.0159	CbGbCtD
Alfentanil—ABCB1—Gemcitabine—breast cancer	0.00773	0.0158	CbGbCtD
Alfentanil—ABCB1—Paclitaxel—breast cancer	0.00698	0.0143	CbGbCtD
Alfentanil—ALB—Methotrexate—breast cancer	0.00697	0.0143	CbGbCtD
Alfentanil—ABCB1—Irinotecan—breast cancer	0.00689	0.0141	CbGbCtD
Alfentanil—ABCB1—Vinblastine—breast cancer	0.00612	0.0126	CbGbCtD
Alfentanil—CYP3A4—Vinorelbine—breast cancer	0.00595	0.0122	CbGbCtD
Alfentanil—CYP3A4—Tamoxifen—breast cancer	0.00537	0.011	CbGbCtD
Alfentanil—CYP3A4—Mitoxantrone—breast cancer	0.00524	0.0107	CbGbCtD
Alfentanil—ABCB1—Docetaxel—breast cancer	0.00505	0.0104	CbGbCtD
Alfentanil—CYP3A4—Paclitaxel—breast cancer	0.00418	0.00858	CbGbCtD
Alfentanil—CYP3A4—Irinotecan—breast cancer	0.00413	0.00846	CbGbCtD
Alfentanil—ABCB1—Doxorubicin—breast cancer	0.00376	0.00772	CbGbCtD
Alfentanil—CYP3A4—Vinblastine—breast cancer	0.00367	0.00752	CbGbCtD
Alfentanil—ABCB1—Methotrexate—breast cancer	0.00364	0.00747	CbGbCtD
Alfentanil—CYP3A4—Docetaxel—breast cancer	0.00302	0.0062	CbGbCtD
Alfentanil—CYP3A4—Doxorubicin—breast cancer	0.00225	0.00462	CbGbCtD
Alfentanil—Sufentanil—CYP3A4—breast cancer	0.000225	0.616	CrCbGaD
Alfentanil—Anaphylactic shock—Paclitaxel—breast cancer	9.99e-05	0.000748	CcSEcCtD
Alfentanil—Nausea—Goserelin—breast cancer	9.85e-05	0.000737	CcSEcCtD
Alfentanil—Feeling abnormal—Gemcitabine—breast cancer	9.83e-05	0.000736	CcSEcCtD
Alfentanil—Dizziness—Vinorelbine—breast cancer	9.82e-05	0.000735	CcSEcCtD
Alfentanil—Nervous system disorder—Paclitaxel—breast cancer	9.8e-05	0.000733	CcSEcCtD
Alfentanil—Tachycardia—Paclitaxel—breast cancer	9.75e-05	0.00073	CcSEcCtD
Alfentanil—Urticaria—Mitoxantrone—breast cancer	9.73e-05	0.000729	CcSEcCtD
Alfentanil—Skin disorder—Paclitaxel—breast cancer	9.7e-05	0.000726	CcSEcCtD
Alfentanil—Body temperature increased—Mitoxantrone—breast cancer	9.68e-05	0.000725	CcSEcCtD
Alfentanil—Body temperature increased—Irinotecan—breast cancer	9.68e-05	0.000725	CcSEcCtD
Alfentanil—Feeling abnormal—Fluorouracil—breast cancer	9.67e-05	0.000724	CcSEcCtD
Alfentanil—Hyperhidrosis—Paclitaxel—breast cancer	9.66e-05	0.000723	CcSEcCtD
Alfentanil—Drowsiness—Methotrexate—breast cancer	9.57e-05	0.000716	CcSEcCtD
Alfentanil—Vision blurred—Capecitabine—breast cancer	9.47e-05	0.000709	CcSEcCtD
Alfentanil—Vomiting—Vinorelbine—breast cancer	9.44e-05	0.000707	CcSEcCtD
Alfentanil—Body temperature increased—Gemcitabine—breast cancer	9.43e-05	0.000706	CcSEcCtD
Alfentanil—Dizziness—Thiotepa—breast cancer	9.38e-05	0.000702	CcSEcCtD
Alfentanil—Rash—Vinorelbine—breast cancer	9.36e-05	0.000701	CcSEcCtD
Alfentanil—Dermatitis—Vinorelbine—breast cancer	9.36e-05	0.0007	CcSEcCtD
Alfentanil—Hypotension—Paclitaxel—breast cancer	9.33e-05	0.000699	CcSEcCtD
Alfentanil—Urticaria—Fluorouracil—breast cancer	9.32e-05	0.000698	CcSEcCtD
Alfentanil—Headache—Vinorelbine—breast cancer	9.3e-05	0.000697	CcSEcCtD
Alfentanil—Body temperature increased—Fluorouracil—breast cancer	9.27e-05	0.000694	CcSEcCtD
Alfentanil—Loss of consciousness—Docetaxel—breast cancer	9.12e-05	0.000683	CcSEcCtD
Alfentanil—Cough—Docetaxel—breast cancer	9.05e-05	0.000678	CcSEcCtD
Alfentanil—Epistaxis—Methotrexate—breast cancer	9.03e-05	0.000676	CcSEcCtD
Alfentanil—Hypersensitivity—Mitoxantrone—breast cancer	9.02e-05	0.000676	CcSEcCtD
Alfentanil—Hypersensitivity—Irinotecan—breast cancer	9.02e-05	0.000676	CcSEcCtD
Alfentanil—Vomiting—Thiotepa—breast cancer	9.02e-05	0.000675	CcSEcCtD
Alfentanil—Convulsion—Docetaxel—breast cancer	8.99e-05	0.000673	CcSEcCtD
Alfentanil—Hypertension—Docetaxel—breast cancer	8.96e-05	0.000671	CcSEcCtD
Alfentanil—Drowsiness—Epirubicin—breast cancer	8.95e-05	0.00067	CcSEcCtD
Alfentanil—Rash—Thiotepa—breast cancer	8.94e-05	0.00067	CcSEcCtD
Alfentanil—Dermatitis—Thiotepa—breast cancer	8.93e-05	0.000669	CcSEcCtD
Alfentanil—Headache—Thiotepa—breast cancer	8.89e-05	0.000665	CcSEcCtD
Alfentanil—Somnolence—Paclitaxel—breast cancer	8.88e-05	0.000665	CcSEcCtD
Alfentanil—Loss of consciousness—Capecitabine—breast cancer	8.83e-05	0.000661	CcSEcCtD
Alfentanil—Nausea—Vinorelbine—breast cancer	8.82e-05	0.00066	CcSEcCtD
Alfentanil—Asthenia—Irinotecan—breast cancer	8.79e-05	0.000658	CcSEcCtD
Alfentanil—Asthenia—Mitoxantrone—breast cancer	8.79e-05	0.000658	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.77e-05	0.000657	CcSEcCtD
Alfentanil—Cough—Capecitabine—breast cancer	8.77e-05	0.000656	CcSEcCtD
Alfentanil—Hypertension—Capecitabine—breast cancer	8.67e-05	0.000649	CcSEcCtD
Alfentanil—Hypersensitivity—Fluorouracil—breast cancer	8.64e-05	0.000647	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Paclitaxel—breast cancer	8.62e-05	0.000646	CcSEcCtD
Alfentanil—Fatigue—Paclitaxel—breast cancer	8.61e-05	0.000645	CcSEcCtD
Alfentanil—Asthenia—Gemcitabine—breast cancer	8.56e-05	0.000641	CcSEcCtD
Alfentanil—Pain—Paclitaxel—breast cancer	8.54e-05	0.00064	CcSEcCtD
Alfentanil—Confusional state—Docetaxel—breast cancer	8.54e-05	0.000639	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	8.49e-05	0.000636	CcSEcCtD
Alfentanil—Anaphylactic shock—Docetaxel—breast cancer	8.47e-05	0.000634	CcSEcCtD
Alfentanil—Epistaxis—Epirubicin—breast cancer	8.45e-05	0.000632	CcSEcCtD
Alfentanil—Pruritus—Gemcitabine—breast cancer	8.44e-05	0.000632	CcSEcCtD
Alfentanil—Nausea—Thiotepa—breast cancer	8.42e-05	0.000631	CcSEcCtD
Alfentanil—Nervous system disorder—Docetaxel—breast cancer	8.3e-05	0.000622	CcSEcCtD
Alfentanil—Pruritus—Fluorouracil—breast cancer	8.3e-05	0.000621	CcSEcCtD
Alfentanil—Drowsiness—Doxorubicin—breast cancer	8.29e-05	0.00062	CcSEcCtD
Alfentanil—Visual impairment—Methotrexate—breast cancer	8.28e-05	0.00062	CcSEcCtD
Alfentanil—Confusional state—Capecitabine—breast cancer	8.27e-05	0.000619	CcSEcCtD
Alfentanil—Tachycardia—Docetaxel—breast cancer	8.26e-05	0.000619	CcSEcCtD
Alfentanil—Feeling abnormal—Paclitaxel—breast cancer	8.23e-05	0.000616	CcSEcCtD
Alfentanil—Skin disorder—Docetaxel—breast cancer	8.22e-05	0.000616	CcSEcCtD
Alfentanil—Bradycardia—Epirubicin—breast cancer	8.18e-05	0.000613	CcSEcCtD
Alfentanil—Dizziness—Irinotecan—breast cancer	8.1e-05	0.000606	CcSEcCtD
Alfentanil—Nervous system disorder—Capecitabine—breast cancer	8.04e-05	0.000602	CcSEcCtD
Alfentanil—Eye disorder—Methotrexate—breast cancer	8.03e-05	0.000601	CcSEcCtD
Alfentanil—Tachycardia—Capecitabine—breast cancer	8e-05	0.000599	CcSEcCtD
Alfentanil—Cardiac disorder—Methotrexate—breast cancer	7.97e-05	0.000597	CcSEcCtD
Alfentanil—Skin disorder—Capecitabine—breast cancer	7.96e-05	0.000596	CcSEcCtD
Alfentanil—Urticaria—Paclitaxel—breast cancer	7.94e-05	0.000594	CcSEcCtD
Alfentanil—Hyperhidrosis—Capecitabine—breast cancer	7.93e-05	0.000593	CcSEcCtD
Alfentanil—Hypotension—Docetaxel—breast cancer	7.91e-05	0.000592	CcSEcCtD
Alfentanil—Connective tissue disorder—Epirubicin—breast cancer	7.9e-05	0.000591	CcSEcCtD
Alfentanil—Body temperature increased—Paclitaxel—breast cancer	7.9e-05	0.000591	CcSEcCtD
Alfentanil—Epistaxis—Doxorubicin—breast cancer	7.82e-05	0.000585	CcSEcCtD
Alfentanil—Angiopathy—Methotrexate—breast cancer	7.79e-05	0.000583	CcSEcCtD
Alfentanil—Vomiting—Irinotecan—breast cancer	7.79e-05	0.000583	CcSEcCtD
Alfentanil—Vomiting—Mitoxantrone—breast cancer	7.79e-05	0.000583	CcSEcCtD
Alfentanil—Immune system disorder—Methotrexate—breast cancer	7.76e-05	0.000581	CcSEcCtD
Alfentanil—Dizziness—Fluorouracil—breast cancer	7.76e-05	0.000581	CcSEcCtD
Alfentanil—Visual impairment—Epirubicin—breast cancer	7.75e-05	0.00058	CcSEcCtD
Alfentanil—Mediastinal disorder—Methotrexate—breast cancer	7.74e-05	0.00058	CcSEcCtD
Alfentanil—Rash—Mitoxantrone—breast cancer	7.72e-05	0.000578	CcSEcCtD
Alfentanil—Rash—Irinotecan—breast cancer	7.72e-05	0.000578	CcSEcCtD
Alfentanil—Dermatitis—Irinotecan—breast cancer	7.72e-05	0.000578	CcSEcCtD
Alfentanil—Dermatitis—Mitoxantrone—breast cancer	7.72e-05	0.000578	CcSEcCtD
Alfentanil—Chills—Methotrexate—breast cancer	7.71e-05	0.000577	CcSEcCtD
Alfentanil—Headache—Mitoxantrone—breast cancer	7.67e-05	0.000574	CcSEcCtD
Alfentanil—Headache—Irinotecan—breast cancer	7.67e-05	0.000574	CcSEcCtD
Alfentanil—Hypotension—Capecitabine—breast cancer	7.66e-05	0.000574	CcSEcCtD
Alfentanil—Fentanyl—CYP3A4—breast cancer	7.65e-05	0.21	CrCbGaD
Alfentanil—Vomiting—Gemcitabine—breast cancer	7.59e-05	0.000568	CcSEcCtD
Alfentanil—Bradycardia—Doxorubicin—breast cancer	7.57e-05	0.000567	CcSEcCtD
Alfentanil—Somnolence—Docetaxel—breast cancer	7.53e-05	0.000564	CcSEcCtD
Alfentanil—Mental disorder—Methotrexate—breast cancer	7.53e-05	0.000563	CcSEcCtD
Alfentanil—Rash—Gemcitabine—breast cancer	7.52e-05	0.000563	CcSEcCtD
Alfentanil—Dermatitis—Gemcitabine—breast cancer	7.52e-05	0.000563	CcSEcCtD
Alfentanil—Eye disorder—Epirubicin—breast cancer	7.51e-05	0.000562	CcSEcCtD
Alfentanil—Erythema—Methotrexate—breast cancer	7.48e-05	0.00056	CcSEcCtD
Alfentanil—Headache—Gemcitabine—breast cancer	7.47e-05	0.00056	CcSEcCtD
Alfentanil—Cardiac disorder—Epirubicin—breast cancer	7.46e-05	0.000559	CcSEcCtD
Alfentanil—Vomiting—Fluorouracil—breast cancer	7.46e-05	0.000558	CcSEcCtD
Alfentanil—Rash—Fluorouracil—breast cancer	7.4e-05	0.000554	CcSEcCtD
Alfentanil—Dermatitis—Fluorouracil—breast cancer	7.39e-05	0.000553	CcSEcCtD
Alfentanil—Hypersensitivity—Paclitaxel—breast cancer	7.36e-05	0.000551	CcSEcCtD
Alfentanil—Headache—Fluorouracil—breast cancer	7.35e-05	0.00055	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Docetaxel—breast cancer	7.31e-05	0.000547	CcSEcCtD
Alfentanil—Connective tissue disorder—Doxorubicin—breast cancer	7.31e-05	0.000547	CcSEcCtD
Alfentanil—Fatigue—Docetaxel—breast cancer	7.3e-05	0.000547	CcSEcCtD
Alfentanil—Angiopathy—Epirubicin—breast cancer	7.29e-05	0.000546	CcSEcCtD
Alfentanil—Nausea—Irinotecan—breast cancer	7.28e-05	0.000545	CcSEcCtD
Alfentanil—Nausea—Mitoxantrone—breast cancer	7.28e-05	0.000545	CcSEcCtD
Alfentanil—Immune system disorder—Epirubicin—breast cancer	7.26e-05	0.000544	CcSEcCtD
Alfentanil—Mediastinal disorder—Epirubicin—breast cancer	7.24e-05	0.000542	CcSEcCtD
Alfentanil—Pain—Docetaxel—breast cancer	7.24e-05	0.000542	CcSEcCtD
Alfentanil—Chills—Epirubicin—breast cancer	7.21e-05	0.00054	CcSEcCtD
Alfentanil—Arrhythmia—Epirubicin—breast cancer	7.18e-05	0.000538	CcSEcCtD
Alfentanil—Visual impairment—Doxorubicin—breast cancer	7.17e-05	0.000537	CcSEcCtD
Alfentanil—Asthenia—Paclitaxel—breast cancer	7.17e-05	0.000537	CcSEcCtD
Alfentanil—Nausea—Gemcitabine—breast cancer	7.09e-05	0.000531	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Capecitabine—breast cancer	7.08e-05	0.00053	CcSEcCtD
Alfentanil—Fatigue—Capecitabine—breast cancer	7.07e-05	0.000529	CcSEcCtD
Alfentanil—Pruritus—Paclitaxel—breast cancer	7.07e-05	0.000529	CcSEcCtD
Alfentanil—Vision blurred—Methotrexate—breast cancer	7.05e-05	0.000528	CcSEcCtD
Alfentanil—Mental disorder—Epirubicin—breast cancer	7.04e-05	0.000527	CcSEcCtD
Alfentanil—Pain—Capecitabine—breast cancer	7.01e-05	0.000525	CcSEcCtD
Alfentanil—Erythema—Epirubicin—breast cancer	7e-05	0.000524	CcSEcCtD
Alfentanil—Feeling abnormal—Docetaxel—breast cancer	6.98e-05	0.000522	CcSEcCtD
Alfentanil—Nausea—Fluorouracil—breast cancer	6.97e-05	0.000522	CcSEcCtD
Alfentanil—Eye disorder—Doxorubicin—breast cancer	6.95e-05	0.00052	CcSEcCtD
Alfentanil—Cardiac disorder—Doxorubicin—breast cancer	6.9e-05	0.000517	CcSEcCtD
Alfentanil—Feeling abnormal—Capecitabine—breast cancer	6.76e-05	0.000506	CcSEcCtD
Alfentanil—Angiopathy—Doxorubicin—breast cancer	6.75e-05	0.000505	CcSEcCtD
Alfentanil—Immune system disorder—Doxorubicin—breast cancer	6.72e-05	0.000503	CcSEcCtD
Alfentanil—Mediastinal disorder—Doxorubicin—breast cancer	6.7e-05	0.000502	CcSEcCtD
Alfentanil—Body temperature increased—Docetaxel—breast cancer	6.69e-05	0.000501	CcSEcCtD
Alfentanil—Chills—Doxorubicin—breast cancer	6.67e-05	0.0005	CcSEcCtD
Alfentanil—Arrhythmia—Doxorubicin—breast cancer	6.64e-05	0.000497	CcSEcCtD
Alfentanil—Dizziness—Paclitaxel—breast cancer	6.61e-05	0.000495	CcSEcCtD
Alfentanil—Vision blurred—Epirubicin—breast cancer	6.59e-05	0.000494	CcSEcCtD
Alfentanil—Cough—Methotrexate—breast cancer	6.53e-05	0.000489	CcSEcCtD
Alfentanil—Mental disorder—Doxorubicin—breast cancer	6.52e-05	0.000488	CcSEcCtD
Alfentanil—Urticaria—Capecitabine—breast cancer	6.51e-05	0.000488	CcSEcCtD
Alfentanil—Body temperature increased—Capecitabine—breast cancer	6.48e-05	0.000485	CcSEcCtD
Alfentanil—Convulsion—Methotrexate—breast cancer	6.48e-05	0.000485	CcSEcCtD
Alfentanil—Erythema—Doxorubicin—breast cancer	6.47e-05	0.000485	CcSEcCtD
Alfentanil—Agitation—Epirubicin—breast cancer	6.43e-05	0.000481	CcSEcCtD
Alfentanil—Fentanyl—ABCB1—breast cancer	6.37e-05	0.174	CrCbGaD
Alfentanil—Vomiting—Paclitaxel—breast cancer	6.35e-05	0.000476	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.32e-05	0.000473	CcSEcCtD
Alfentanil—Rash—Paclitaxel—breast cancer	6.3e-05	0.000472	CcSEcCtD
Alfentanil—Dermatitis—Paclitaxel—breast cancer	6.29e-05	0.000471	CcSEcCtD
Alfentanil—Headache—Paclitaxel—breast cancer	6.26e-05	0.000469	CcSEcCtD
Alfentanil—Hypersensitivity—Docetaxel—breast cancer	6.24e-05	0.000467	CcSEcCtD
Alfentanil—Confusional state—Methotrexate—breast cancer	6.15e-05	0.000461	CcSEcCtD
Alfentanil—Loss of consciousness—Epirubicin—breast cancer	6.15e-05	0.00046	CcSEcCtD
Alfentanil—Cough—Epirubicin—breast cancer	6.11e-05	0.000457	CcSEcCtD
Alfentanil—Anaphylactic shock—Methotrexate—breast cancer	6.1e-05	0.000457	CcSEcCtD
Alfentanil—Vision blurred—Doxorubicin—breast cancer	6.1e-05	0.000457	CcSEcCtD
Alfentanil—Asthenia—Docetaxel—breast cancer	6.08e-05	0.000455	CcSEcCtD
Alfentanil—Convulsion—Epirubicin—breast cancer	6.06e-05	0.000454	CcSEcCtD
Alfentanil—Hypertension—Epirubicin—breast cancer	6.04e-05	0.000452	CcSEcCtD
Alfentanil—Hypersensitivity—Capecitabine—breast cancer	6.04e-05	0.000452	CcSEcCtD
Alfentanil—Pruritus—Docetaxel—breast cancer	5.99e-05	0.000448	CcSEcCtD
Alfentanil—Nervous system disorder—Methotrexate—breast cancer	5.98e-05	0.000448	CcSEcCtD
Alfentanil—Agitation—Doxorubicin—breast cancer	5.95e-05	0.000445	CcSEcCtD
Alfentanil—Nausea—Paclitaxel—breast cancer	5.93e-05	0.000444	CcSEcCtD
Alfentanil—Skin disorder—Methotrexate—breast cancer	5.93e-05	0.000444	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.92e-05	0.000443	CcSEcCtD
Alfentanil—Hyperhidrosis—Methotrexate—breast cancer	5.9e-05	0.000442	CcSEcCtD
Alfentanil—Asthenia—Capecitabine—breast cancer	5.88e-05	0.00044	CcSEcCtD
Alfentanil—Pruritus—Capecitabine—breast cancer	5.8e-05	0.000434	CcSEcCtD
Alfentanil—Confusional state—Epirubicin—breast cancer	5.76e-05	0.000431	CcSEcCtD
Alfentanil—Anaphylactic shock—Epirubicin—breast cancer	5.71e-05	0.000428	CcSEcCtD
Alfentanil—Hypotension—Methotrexate—breast cancer	5.7e-05	0.000427	CcSEcCtD
Alfentanil—Loss of consciousness—Doxorubicin—breast cancer	5.69e-05	0.000426	CcSEcCtD
Alfentanil—Cough—Doxorubicin—breast cancer	5.65e-05	0.000423	CcSEcCtD
Alfentanil—Convulsion—Doxorubicin—breast cancer	5.61e-05	0.00042	CcSEcCtD
Alfentanil—Nervous system disorder—Epirubicin—breast cancer	5.6e-05	0.000419	CcSEcCtD
Alfentanil—Dizziness—Docetaxel—breast cancer	5.6e-05	0.000419	CcSEcCtD
Alfentanil—Hypertension—Doxorubicin—breast cancer	5.59e-05	0.000419	CcSEcCtD
Alfentanil—Tachycardia—Epirubicin—breast cancer	5.57e-05	0.000417	CcSEcCtD
Alfentanil—Skin disorder—Epirubicin—breast cancer	5.55e-05	0.000415	CcSEcCtD
Alfentanil—Hyperhidrosis—Epirubicin—breast cancer	5.52e-05	0.000413	CcSEcCtD
Alfentanil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.47e-05	0.00041	CcSEcCtD
Alfentanil—Somnolence—Methotrexate—breast cancer	5.43e-05	0.000406	CcSEcCtD
Alfentanil—Dizziness—Capecitabine—breast cancer	5.42e-05	0.000406	CcSEcCtD
Alfentanil—Vomiting—Docetaxel—breast cancer	5.38e-05	0.000403	CcSEcCtD
Alfentanil—Rash—Docetaxel—breast cancer	5.34e-05	0.0004	CcSEcCtD
Alfentanil—Hypotension—Epirubicin—breast cancer	5.34e-05	0.0004	CcSEcCtD
Alfentanil—Dermatitis—Docetaxel—breast cancer	5.33e-05	0.000399	CcSEcCtD
Alfentanil—Confusional state—Doxorubicin—breast cancer	5.33e-05	0.000399	CcSEcCtD
Alfentanil—Headache—Docetaxel—breast cancer	5.3e-05	0.000397	CcSEcCtD
Alfentanil—Anaphylactic shock—Doxorubicin—breast cancer	5.28e-05	0.000396	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Methotrexate—breast cancer	5.27e-05	0.000394	CcSEcCtD
Alfentanil—Fatigue—Methotrexate—breast cancer	5.26e-05	0.000394	CcSEcCtD
Alfentanil—Pain—Methotrexate—breast cancer	5.22e-05	0.000391	CcSEcCtD
Alfentanil—Vomiting—Capecitabine—breast cancer	5.21e-05	0.00039	CcSEcCtD
Alfentanil—Nervous system disorder—Doxorubicin—breast cancer	5.18e-05	0.000388	CcSEcCtD
Alfentanil—Rash—Capecitabine—breast cancer	5.17e-05	0.000387	CcSEcCtD
Alfentanil—Dermatitis—Capecitabine—breast cancer	5.16e-05	0.000387	CcSEcCtD
Alfentanil—Tachycardia—Doxorubicin—breast cancer	5.16e-05	0.000386	CcSEcCtD
Alfentanil—Headache—Capecitabine—breast cancer	5.14e-05	0.000384	CcSEcCtD
Alfentanil—Skin disorder—Doxorubicin—breast cancer	5.13e-05	0.000384	CcSEcCtD
Alfentanil—Hyperhidrosis—Doxorubicin—breast cancer	5.11e-05	0.000382	CcSEcCtD
Alfentanil—Somnolence—Epirubicin—breast cancer	5.08e-05	0.00038	CcSEcCtD
Alfentanil—Nausea—Docetaxel—breast cancer	5.03e-05	0.000377	CcSEcCtD
Alfentanil—Feeling abnormal—Methotrexate—breast cancer	5.03e-05	0.000377	CcSEcCtD
Alfentanil—Hypotension—Doxorubicin—breast cancer	4.94e-05	0.00037	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Epirubicin—breast cancer	4.93e-05	0.000369	CcSEcCtD
Alfentanil—Fatigue—Epirubicin—breast cancer	4.92e-05	0.000369	CcSEcCtD
Alfentanil—Pain—Epirubicin—breast cancer	4.88e-05	0.000366	CcSEcCtD
Alfentanil—Nausea—Capecitabine—breast cancer	4.87e-05	0.000365	CcSEcCtD
Alfentanil—Urticaria—Methotrexate—breast cancer	4.85e-05	0.000363	CcSEcCtD
Alfentanil—Body temperature increased—Methotrexate—breast cancer	4.82e-05	0.000361	CcSEcCtD
Alfentanil—Feeling abnormal—Epirubicin—breast cancer	4.71e-05	0.000352	CcSEcCtD
Alfentanil—Somnolence—Doxorubicin—breast cancer	4.7e-05	0.000352	CcSEcCtD
Alfentanil—Gastrointestinal disorder—Doxorubicin—breast cancer	4.56e-05	0.000342	CcSEcCtD
Alfentanil—Fatigue—Doxorubicin—breast cancer	4.56e-05	0.000341	CcSEcCtD
Alfentanil—Urticaria—Epirubicin—breast cancer	4.54e-05	0.00034	CcSEcCtD
Alfentanil—Pain—Doxorubicin—breast cancer	4.52e-05	0.000338	CcSEcCtD
Alfentanil—Body temperature increased—Epirubicin—breast cancer	4.51e-05	0.000338	CcSEcCtD
Alfentanil—Hypersensitivity—Methotrexate—breast cancer	4.5e-05	0.000337	CcSEcCtD
Alfentanil—Asthenia—Methotrexate—breast cancer	4.38e-05	0.000328	CcSEcCtD
Alfentanil—Feeling abnormal—Doxorubicin—breast cancer	4.35e-05	0.000326	CcSEcCtD
Alfentanil—Pruritus—Methotrexate—breast cancer	4.32e-05	0.000323	CcSEcCtD
Alfentanil—Hypersensitivity—Epirubicin—breast cancer	4.21e-05	0.000315	CcSEcCtD
Alfentanil—Urticaria—Doxorubicin—breast cancer	4.2e-05	0.000314	CcSEcCtD
Alfentanil—Body temperature increased—Doxorubicin—breast cancer	4.18e-05	0.000313	CcSEcCtD
Alfentanil—Asthenia—Epirubicin—breast cancer	4.1e-05	0.000307	CcSEcCtD
Alfentanil—Pruritus—Epirubicin—breast cancer	4.04e-05	0.000303	CcSEcCtD
Alfentanil—Dizziness—Methotrexate—breast cancer	4.04e-05	0.000302	CcSEcCtD
Alfentanil—Hypersensitivity—Doxorubicin—breast cancer	3.89e-05	0.000291	CcSEcCtD
Alfentanil—Vomiting—Methotrexate—breast cancer	3.88e-05	0.00029	CcSEcCtD
Alfentanil—Rash—Methotrexate—breast cancer	3.85e-05	0.000288	CcSEcCtD
Alfentanil—Dermatitis—Methotrexate—breast cancer	3.84e-05	0.000288	CcSEcCtD
Alfentanil—Headache—Methotrexate—breast cancer	3.82e-05	0.000286	CcSEcCtD
Alfentanil—Asthenia—Doxorubicin—breast cancer	3.79e-05	0.000284	CcSEcCtD
Alfentanil—Dizziness—Epirubicin—breast cancer	3.78e-05	0.000283	CcSEcCtD
Alfentanil—Pruritus—Doxorubicin—breast cancer	3.74e-05	0.00028	CcSEcCtD
Alfentanil—Vomiting—Epirubicin—breast cancer	3.63e-05	0.000272	CcSEcCtD
Alfentanil—Nausea—Methotrexate—breast cancer	3.62e-05	0.000271	CcSEcCtD
Alfentanil—Rash—Epirubicin—breast cancer	3.6e-05	0.00027	CcSEcCtD
Alfentanil—Dermatitis—Epirubicin—breast cancer	3.6e-05	0.000269	CcSEcCtD
Alfentanil—Headache—Epirubicin—breast cancer	3.58e-05	0.000268	CcSEcCtD
Alfentanil—Dizziness—Doxorubicin—breast cancer	3.49e-05	0.000262	CcSEcCtD
Alfentanil—Nausea—Epirubicin—breast cancer	3.39e-05	0.000254	CcSEcCtD
Alfentanil—Vomiting—Doxorubicin—breast cancer	3.36e-05	0.000252	CcSEcCtD
Alfentanil—Rash—Doxorubicin—breast cancer	3.33e-05	0.000249	CcSEcCtD
Alfentanil—Dermatitis—Doxorubicin—breast cancer	3.33e-05	0.000249	CcSEcCtD
Alfentanil—Headache—Doxorubicin—breast cancer	3.31e-05	0.000248	CcSEcCtD
Alfentanil—Nausea—Doxorubicin—breast cancer	3.14e-05	0.000235	CcSEcCtD
Alfentanil—ABCB1—Metabolism—ACHE—breast cancer	5.84e-06	0.000103	CbGpPWpGaD
Alfentanil—ALB—Metabolism—FASN—breast cancer	5.83e-06	0.000103	CbGpPWpGaD
Alfentanil—ALB—Metabolism—BCHE—breast cancer	5.81e-06	0.000102	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP19A1—breast cancer	5.8e-06	0.000102	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—STK11—breast cancer	5.8e-06	0.000102	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—BRIP1—breast cancer	5.76e-06	0.000101	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HPSE—breast cancer	5.76e-06	0.000101	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—LDHB—breast cancer	5.76e-06	0.000101	CbGpPWpGaD
Alfentanil—ALB—Platelet activation, signaling and aggregation—AKT1—breast cancer	5.76e-06	0.000101	CbGpPWpGaD
Alfentanil—ALB—Metabolism—SLC5A5—breast cancer	5.74e-06	0.000101	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—FGFR1—breast cancer	5.67e-06	9.98e-05	CbGpPWpGaD
Alfentanil—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	5.67e-06	9.97e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—HIF1A—breast cancer	5.59e-06	9.83e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—CAV1—breast cancer	5.56e-06	9.78e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NQO1—breast cancer	5.54e-06	9.74e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—SLC2A1—breast cancer	5.54e-06	9.74e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP17A1—breast cancer	5.53e-06	9.72e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ENO1—breast cancer	5.47e-06	9.63e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PTGS1—breast cancer	5.47e-06	9.63e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—IL2—breast cancer	5.47e-06	9.62e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HMMR—breast cancer	5.46e-06	9.6e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTA3—breast cancer	5.46e-06	9.6e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ABCC1—breast cancer	5.46e-06	9.6e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—LEP—breast cancer	5.46e-06	9.6e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.42e-06	9.54e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CAV1—breast cancer	5.41e-06	9.51e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP3A4—breast cancer	5.4e-06	9.5e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—COMT—breast cancer	5.39e-06	9.48e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.37e-06	9.45e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP2D6—breast cancer	5.37e-06	9.44e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTP1—breast cancer	5.36e-06	9.44e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—KDR—breast cancer	5.34e-06	9.4e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP1B1—breast cancer	5.31e-06	9.34e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—HMOX1—breast cancer	5.29e-06	9.31e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PPARGC1B—breast cancer	5.29e-06	9.3e-05	CbGpPWpGaD
Alfentanil—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	5.28e-06	9.29e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ITPR1—breast cancer	5.28e-06	9.28e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NCOA2—breast cancer	5.27e-06	9.27e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ESR1—breast cancer	5.21e-06	9.16e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—HSP90AA1—breast cancer	5.21e-06	9.16e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—FN1—breast cancer	5.14e-06	9.05e-05	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	5.12e-06	9e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—FASN—breast cancer	5.11e-06	8.99e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—BCHE—breast cancer	5.09e-06	8.95e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—NFKBIA—breast cancer	5.08e-06	8.94e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ABCB1—breast cancer	5.08e-06	8.93e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NCOA1—breast cancer	5.07e-06	8.91e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PIK3CG—breast cancer	5.06e-06	8.91e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—NOTCH1—breast cancer	5.03e-06	8.86e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—SLC5A5—breast cancer	5.03e-06	8.84e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP19A1—breast cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—STK11—breast cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CA9—breast cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTA4—breast cancer	4.99e-06	8.78e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—TYMS—breast cancer	4.99e-06	8.77e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NCOR1—breast cancer	4.93e-06	8.67e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PLA2G4A—breast cancer	4.93e-06	8.67e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GSTM1—breast cancer	4.93e-06	8.67e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—APC—breast cancer	4.92e-06	8.66e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PIK3CG—breast cancer	4.92e-06	8.66e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—KIT—breast cancer	4.92e-06	8.66e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—EGF—breast cancer	4.87e-06	8.56e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTA2—breast cancer	4.86e-06	8.56e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPX2—breast cancer	4.86e-06	8.56e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—SLC2A1—breast cancer	4.85e-06	8.54e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NQO1—breast cancer	4.85e-06	8.54e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SULT1A1—breast cancer	4.8e-06	8.45e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPX4—breast cancer	4.8e-06	8.45e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—SRC—breast cancer	4.77e-06	8.4e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP3A4—breast cancer	4.73e-06	8.33e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—GPX1—breast cancer	4.72e-06	8.3e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—MAPK3—breast cancer	4.72e-06	8.29e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—IDH1—breast cancer	4.69e-06	8.25e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTA1—breast cancer	4.69e-06	8.25e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.69e-06	8.24e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CYP1A1—breast cancer	4.67e-06	8.22e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP1B1—breast cancer	4.65e-06	8.18e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—VEGFA—breast cancer	4.65e-06	8.18e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—COMT—breast cancer	4.64e-06	8.17e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NAT2—breast cancer	4.64e-06	8.16e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ERCC2—breast cancer	4.63e-06	8.15e-05	CbGpPWpGaD
Alfentanil—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	4.63e-06	8.14e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—BRAF—breast cancer	4.63e-06	8.14e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTP1—breast cancer	4.62e-06	8.13e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—HSP90AA1—breast cancer	4.56e-06	8.03e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—HMOX1—breast cancer	4.56e-06	8.01e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ITPR1—breast cancer	4.55e-06	8e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IGF1—breast cancer	4.51e-06	7.93e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—AKT2—breast cancer	4.5e-06	7.92e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—EGFR—breast cancer	4.49e-06	7.89e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PIK3CD—breast cancer	4.45e-06	7.83e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NCOA1—breast cancer	4.44e-06	7.81e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—MAPK3—breast cancer	4.4e-06	7.74e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—ALB—breast cancer	4.39e-06	7.73e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—STK11—breast cancer	4.37e-06	7.7e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP19A1—breast cancer	4.37e-06	7.7e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ABCB1—breast cancer	4.37e-06	7.69e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—MTHFR—breast cancer	4.36e-06	7.66e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PIK3CD—breast cancer	4.33e-06	7.61e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—TYMS—breast cancer	4.3e-06	7.55e-05	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—PIK3CA—breast cancer	4.29e-06	7.54e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SERPINE1—breast cancer	4.28e-06	7.53e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TGFB1—breast cancer	4.27e-06	7.51e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PLA2G4A—breast cancer	4.25e-06	7.47e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GSTM1—breast cancer	4.25e-06	7.47e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NCOR1—breast cancer	4.25e-06	7.47e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—KRAS—breast cancer	4.24e-06	7.45e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—NOS3—breast cancer	4.2e-06	7.39e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—NOS3—breast cancer	4.09e-06	7.19e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MED12—breast cancer	4.07e-06	7.16e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—DPYD—breast cancer	4.07e-06	7.16e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—COMT—breast cancer	4.07e-06	7.15e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—GPX1—breast cancer	4.07e-06	7.15e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTP1—breast cancer	4.05e-06	7.12e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CYP1A1—breast cancer	4.02e-06	7.08e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—CAV1—breast cancer	4.02e-06	7.07e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ALDOA—breast cancer	4.01e-06	7.05e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—HMOX1—breast cancer	3.99e-06	7.02e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—ERCC2—breast cancer	3.99e-06	7.02e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ITPR1—breast cancer	3.98e-06	7.01e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—KRAS—breast cancer	3.95e-06	6.95e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—PIK3CA—breast cancer	3.89e-06	6.85e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NCOA3—breast cancer	3.89e-06	6.84e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PIK3CB—breast cancer	3.88e-06	6.83e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MDM2—breast cancer	3.88e-06	6.82e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RAF1—breast cancer	3.86e-06	6.8e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SLC2A2—breast cancer	3.86e-06	6.79e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—RELA—breast cancer	3.85e-06	6.77e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PTGS2—breast cancer	3.84e-06	6.76e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—ERBB2—breast cancer	3.82e-06	6.72e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ABCG2—breast cancer	3.78e-06	6.65e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CPT1A—breast cancer	3.78e-06	6.65e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MTR—breast cancer	3.78e-06	6.65e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MTOR—breast cancer	3.77e-06	6.64e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PIK3CB—breast cancer	3.77e-06	6.64e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—TYMS—breast cancer	3.76e-06	6.62e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—MTHFR—breast cancer	3.75e-06	6.6e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PLA2G4A—breast cancer	3.72e-06	6.54e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GSTM1—breast cancer	3.72e-06	6.54e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NCOR1—breast cancer	3.72e-06	6.54e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HPGDS—breast cancer	3.71e-06	6.53e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HBA1—breast cancer	3.69e-06	6.48e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PIK3CG—breast cancer	3.66e-06	6.44e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—PIK3CA—breast cancer	3.63e-06	6.39e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CXCL8—breast cancer	3.63e-06	6.38e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—HRAS—breast cancer	3.6e-06	6.34e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ACHE—breast cancer	3.6e-06	6.33e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTT1—breast cancer	3.6e-06	6.33e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—GPX1—breast cancer	3.56e-06	6.27e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CDKN1B—breast cancer	3.54e-06	6.23e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CYP1A1—breast cancer	3.53e-06	6.2e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—TP53—breast cancer	3.51e-06	6.18e-05	CbGpPWpGaD
Alfentanil—OPRM1—GPCR downstream signaling—AKT1—breast cancer	3.5e-06	6.16e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ERCC2—breast cancer	3.5e-06	6.15e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CASP3—breast cancer	3.47e-06	6.1e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL2—breast cancer	3.46e-06	6.09e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—CAV1—breast cancer	3.46e-06	6.09e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—IL6—breast cancer	3.45e-06	6.06e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP17A1—breast cancer	3.41e-06	5.99e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CCND1—breast cancer	3.38e-06	5.94e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ENO1—breast cancer	3.37e-06	5.93e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PTGS1—breast cancer	3.37e-06	5.93e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—JUN—breast cancer	3.37e-06	5.93e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—HRAS—breast cancer	3.36e-06	5.91e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PTEN—breast cancer	3.35e-06	5.9e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CTNNB1—breast cancer	3.34e-06	5.88e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.31e-06	5.82e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP2D6—breast cancer	3.31e-06	5.82e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—MTHFR—breast cancer	3.29e-06	5.78e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MMP9—breast cancer	3.28e-06	5.77e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—CDKN1A—breast cancer	3.27e-06	5.75e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PTEN—breast cancer	3.26e-06	5.73e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NCOA2—breast cancer	3.25e-06	5.71e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PIK3CD—breast cancer	3.22e-06	5.66e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MAPK8—breast cancer	3.19e-06	5.61e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling by GPCR—AKT1—breast cancer	3.18e-06	5.59e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—ALB—breast cancer	3.18e-06	5.59e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PIK3CG—breast cancer	3.15e-06	5.55e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—FASN—breast cancer	3.15e-06	5.54e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—BCHE—breast cancer	3.13e-06	5.51e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SLC5A5—breast cancer	3.1e-06	5.45e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—NOS3—breast cancer	3.04e-06	5.34e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—CAV1—breast cancer	3.03e-06	5.33e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—SRC—breast cancer	3.02e-06	5.32e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—SLC2A1—breast cancer	2.99e-06	5.26e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NQO1—breast cancer	2.99e-06	5.26e-05	CbGpPWpGaD
Alfentanil—ALB—Hemostasis—AKT1—breast cancer	2.97e-06	5.22e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—VEGFA—breast cancer	2.94e-06	5.18e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—STAT3—breast cancer	2.92e-06	5.13e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP1B1—breast cancer	2.87e-06	5.04e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.81e-06	4.95e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PIK3CB—breast cancer	2.8e-06	4.93e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MAPK3—breast cancer	2.79e-06	4.9e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PTGS2—breast cancer	2.78e-06	4.89e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PIK3CD—breast cancer	2.77e-06	4.87e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PIK3CG—breast cancer	2.76e-06	4.86e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NCOA1—breast cancer	2.73e-06	4.81e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—MYC—breast cancer	2.71e-06	4.77e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TGFB1—breast cancer	2.7e-06	4.75e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP19A1—breast cancer	2.7e-06	4.74e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—STK11—breast cancer	2.7e-06	4.74e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—EGFR—breast cancer	2.65e-06	4.66e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—NOS3—breast cancer	2.62e-06	4.6e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—COMT—breast cancer	2.51e-06	4.41e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—KRAS—breast cancer	2.5e-06	4.4e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTP1—breast cancer	2.49e-06	4.39e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—HMOX1—breast cancer	2.46e-06	4.33e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ITPR1—breast cancer	2.45e-06	4.32e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PIK3CD—breast cancer	2.43e-06	4.27e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PTEN—breast cancer	2.42e-06	4.26e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PIK3CB—breast cancer	2.42e-06	4.25e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—ALB—breast cancer	2.4e-06	4.22e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PTGS2—breast cancer	2.39e-06	4.21e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—PIK3CA—breast cancer	2.37e-06	4.16e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ABCB1—breast cancer	2.36e-06	4.15e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—TYMS—breast cancer	2.32e-06	4.08e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—PIK3CA—breast cancer	2.3e-06	4.05e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—NOS3—breast cancer	2.29e-06	4.03e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.29e-06	4.03e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NCOR1—breast cancer	2.29e-06	4.03e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GSTM1—breast cancer	2.29e-06	4.03e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—TP53—breast cancer	2.22e-06	3.91e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—GPX1—breast cancer	2.19e-06	3.86e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CYP1A1—breast cancer	2.17e-06	3.82e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ERCC2—breast cancer	2.15e-06	3.79e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—HRAS—breast cancer	2.13e-06	3.74e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PIK3CB—breast cancer	2.12e-06	3.72e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PTGS2—breast cancer	2.1e-06	3.69e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PTEN—breast cancer	2.09e-06	3.67e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—IL6—breast cancer	2.04e-06	3.58e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—MTHFR—breast cancer	2.03e-06	3.56e-05	CbGpPWpGaD
Alfentanil—CYP3A7—Metabolism—AKT1—breast cancer	1.93e-06	3.4e-05	CbGpPWpGaD
Alfentanil—OPRM1—Signaling Pathways—AKT1—breast cancer	1.88e-06	3.3e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—CAV1—breast cancer	1.87e-06	3.29e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PTEN—breast cancer	1.83e-06	3.22e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—PIK3CA—breast cancer	1.71e-06	3.01e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PIK3CG—breast cancer	1.7e-06	2.99e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PIK3CD—breast cancer	1.5e-06	2.63e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—ALB—breast cancer	1.48e-06	2.6e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—PIK3CA—breast cancer	1.47e-06	2.59e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—NOS3—breast cancer	1.41e-06	2.48e-05	CbGpPWpGaD
Alfentanil—CYP3A5—Metabolism—AKT1—breast cancer	1.4e-06	2.46e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PIK3CB—breast cancer	1.3e-06	2.29e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PTGS2—breast cancer	1.29e-06	2.27e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—PIK3CA—breast cancer	1.29e-06	2.27e-05	CbGpPWpGaD
Alfentanil—ALB—Metabolism—AKT1—breast cancer	1.2e-06	2.12e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PTEN—breast cancer	1.13e-06	1.98e-05	CbGpPWpGaD
Alfentanil—ABCB1—Metabolism—AKT1—breast cancer	1.05e-06	1.85e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—PIK3CA—breast cancer	7.95e-07	1.4e-05	CbGpPWpGaD
Alfentanil—CYP3A4—Metabolism—AKT1—breast cancer	6.49e-07	1.14e-05	CbGpPWpGaD
